	US 11,998,595 B2
	Telomerase polypeptide vaccine for treating cancer
Gustav Gaudernack, Montebello (NO); Anne-Marie Rasmussen, Montebello (NO); and Else Marit Inderberg Suso, Montebello (NO)
Assigned to Ultimovacs ASA, Oslo (NO)
Filed by Ultimovacs AS, Oslo (NO)
Filed on Dec. 12, 2019, as Appl. No. 16/712,167.
Application 15/498,728 is a division of application No. 13/578,969, granted, now 9,657,068, issued on May 23, 2017, previously published as PCT/EP2011/000980, filed on Feb. 15, 2011.
Application 16/712,167 is a continuation of application No. 15/498,728, filed on Apr. 27, 2017.
Claims priority of application No. 10250265 (EP), filed on Feb. 16, 2010.
Prior Publication US 2020/0121771 A1, Apr. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/435 (2006.01); C12N 9/12 (2006.01); A61K 38/00 (2006.01)

CPC A61K 39/001157 (2018.08) [C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); C12N 9/1276 (2013.01); C12Y 207/07049 (2013.01); A61K 38/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/53 (2013.01)]

15 Claims

1. A pharmaceutical composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a sequence selected from the group consisting of:

i) SEQ ID NO: 1; and

ii) the sequence of a fragment of i) comprising at least 20 amino acids,

wherein the polypeptide is for eliciting a CD4+ and/or a CD8+ T-cell response and further comprises amino acids

at the N and/or C termini that are different from those present in a naturally occurring telomerase enzyme.

and wherein the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant, diluent or excipient.